Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. We developed a six-criterion additive scale for the development of cHIs. The cHIS scale might be helpful in defining target populations for trials and immunomodulatory therapies.

Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial

Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis. The primary endpoint was modified Rodnan Skin Score at 12 months. Clinically meaningful improvements in mRSS and other outcome measures were observed in both the abatacept and placebo groups.

Serious postoperative complications and reoperation after carpal tunnel decompression surgery in England: a nationwide cohort analysis

Of the 855 832 initial surgeries, 620 procedures led to a serious complication within 30 days after surgery. The study is the largest national study on carpal Tunnel Decompression to date. It provides strong evidence of serious postoperative complications.

Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial

Inclusion body myositis is most frequent in patients older than 50 years. In this pilot study, we aimed to test the efficacy of sirolimus in patients with the disease. The study was a randomized, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Canker sores were the most frequent side-effect and were mainly mild or moderate in ten patients.

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Flares of worsening symptoms were reported in one (1%) of 90 patients. Some patients with psoriatic arthritis are stable on tofacitinib.

Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform

Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro. Clinical studies found no evidence of reduced mortality when treating patients with COVID-19. After accounting for age, sex, ethnicity, use of other immunosuppressive drugs, and geographical region, no association with COVID-19 mortality was observed.

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study

We identified 8540 patients with rheumatic and musculoskeletal diseases who were diagnosed with COVID-19. Risk of hospitalisation was lower in the late cohort than in the early cohort. The risks of severe outcomes have improved over time but remain substantial.

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

Belimumab is approved for the treatment of active systemic lupus erythematosus. BASE was a double-blind, randomised, placebo-controlled, phase 4 trial done in 33 countries. Ten patients in the belimumab group died versus eight in the placebo group.

Departments

Recent Posts